Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Leukemia 12Leukemia, Myeloid, Acute 9Lymphoma, Non-Hodgkin 7Lymphoma 7Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Follicular 6Burkitt Lymphoma 6Myelodysplastic Syndromes 5Multiple Myeloma 5Lymphoma, Mantle-Cell 5Blast Crisis 5Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Accelerated Phase 4Waldenstrom Macroglobulinemia 3Neoplasms 3Leukemia, Myelomonocytic, Juvenile 3Leukemia, Lymphocytic, Chronic, B-Cell 3Hodgkin Disease 3Hematologic Neoplasms 3Graft vs Host Disease 3Dendritic Cell Sarcoma, Interdigitating 3Congenital Abnormalities 3Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Anaplastic 2

Interventions

pembrolizumab 23Nivolumab 22aldesleukin 21Cyclophosphamide 20Ipilimumab 17Interleukin-2 17fludarabine 15fludarabine phosphate 14cemiplimab 12Radiotherapy 7Fluorouracil 7Dacarbazine 6binimetinib 5Vemurafenib 5Temozolomide 5Surgical Procedures, Operative 5Sirolimus 5Radiation 5Biopsy 5Aminolevulinic Acid 5encorafenib 4dabrafenib 4Photochemotherapy 4Educational Status 4trametinib 3sonidegib 3montanide ISA 51 3avelumab 3Tacrolimus 3Sodium Chloride 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Skin Neoplasms × Methylprednisolone Hemisuccinate × Clear all
NCT04305145 2026-01-29

Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis

Massachusetts General Hospital

Phase 2 Active not recruiting
42 enrolled
Dermatologic

Colitis, Melanoma, Skin Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡